首页
热心肠日报
文献库
产业库
榜单
关于日报
《肠·道》演讲
往期精彩
《肠·道》2024
《肠·道》2023
《肠·道》2022
《肠·道》2021
《肠·道》2020
《肠·道》2019
《肠·道》2018
《肠·道》2017
关于《肠·道》
肠道大会
热心肠大会
热心肠智库
智库专家
专家动态
智库新闻
关于智库
奖学金
年度人物奖
更多
HOPE
会议信息
科学与艺术
学术专刊
R·AI
周刊
热心肠先生
研究院动态
关于我们
搜索
登录
关闭
手机邮箱登录
扫码登录
微信扫描二维码快捷登录
验证成功,将在
3
秒钟后跳转
已超时,请
重试
关闭
二维码登录
手机登录
邮箱登录
+86
+1
+852
+886
+81
+65
+61
+44
获取验证码
登录 / 注册
关闭
二维码登录
手机登录
邮箱登录
获取验证码
登录 / 注册
热心肠智库
专家文章 | 崔一民
2023
CA
A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes
ADV THER, 10.1007/s12325-023-02536-8
CA
Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study
CLIN TRANSL MED, 10.1002/ctm2.1263
CA
Safety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects
AM J CARDIOVASC DRUG, 10.1007/s40256-023-00585-6
CA
A novel immunogenic cell death-related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer
Front Immunol, 10.3389/fimmu.2023.1162876
CA
Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis
FPHAR, 10.3389/fphar.2023.1132367
FA
CA
Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials
FPHAR, 10.3389/fphar.2023.1163971
CA
Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers
EXPERT OPIN DRUG MET, 10.1080/17425255.2023.2184344
CA
New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF
Front Immunol, 10.3389/fimmu.2023.1098665
CA
Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer
SIGNAL TRANSDUCT TAR, 10.1038/s41392-022-01236-z
CA
The challenges and opportunities of αvβ3-based therapeutics in cancer: From bench to clinical trials
Pharmacol Res, 10.1016/j.phrs.2023.106694
CA
Integrated Pharmacokinetics/Pharmacodynamics Model and Simulation of the Ticagrelor Effect on Patients with Acute Coronary Syndrome
CLIN PHARMACOKINET, 10.1007/s40262-022-01208-0
CA
Urinary Eubacterium sp. CAG:581 Promotes Non-Muscle Invasive Bladder Cancer (NMIBC) Development through the ECM1/MMP9 Pathway
Cancers, 10.3390/cancers15030809
CA
Targeting integrin pathways: mechanisms and advances in therapy
SIGNAL TRANSDUCT TAR, 10.1038/s41392-022-01259-6
2022
CA
Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic-pharmacodynamic profiles of rivaroxaban
HUM GENOMICS, 10.1186/s40246-022-00445-5
CA
Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study
CLIN TRANSL MED, 10.1002/ctm2.1104
CA
Drug-induced fall risk in older patients: A pharmacovigilance study of FDA adverse event reporting system database
FPHAR, 10.3389/fphar.2022.1044744
CA
The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer
Front Immunol, 10.3389/fimmu.2022.1033967
CA
Pharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects
EUR J DRUG METAB PH, 10.1007/s13318-022-00804-6
CA
Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial
J INFECT, 10.1016/j.jinf.2022.11.008
CA
Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation
Front Cardiovasc Med, 10.3389/fcvm.2022.998751